Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
119 hedge funds and large institutions have $564M invested in Paratek Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 48 increasing their positions, 26 reducing their positions, and 15 closing their positions.
126% more call options, than puts
Call options by funds: $7.58M | Put options by funds: $3.35M
113% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 15
85% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 26
45% more capital invested
Capital invested by funds: $389M → $564M (+$174M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
16% more funds holding
Funds holding: 103 → 119 (+16)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.59M |
| 2 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$7.95M |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
+$7.74M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$7.67M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$7.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.5M |
| 2 |
Millennium Management
New York
|
-$10.8M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.4M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$5.08M |
| 5 |
DAM
DLD Asset Management
New York
|
-$4.78M |
PRTK Hedge Fund Activity: Q2 2017 in Review
119 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2017, worth a combined $564M — up 45% from $389M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new PRTK positions and 15 closed out — a net gain of 17 holders — while 48 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $8.59M. The largest seller was Fidelity Investments, cutting an estimated $14.5M.
- 119 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2017, up from 103 in Q1 2017.
- Funds reported $564M of Paratek Pharmaceuticals, Inc. stock for Q2 2017, up 45% quarter-over-quarter.
- 32 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2017 and 15 closed out, a net change of +17 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2017 was BlackRock, an estimated $8.59M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q2 2017 was Fidelity Investments, an estimated $14.5M sold.
Based on aggregated 13F filings for Q2 2017.